- /
- Supported exchanges
- / US
- / ANNX.NASDAQ
Annexon Inc (ANNX NASDAQ) stock market data APIs
Annexon Inc Financial Data Overview
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Annexon Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Annexon Inc data using free add-ons & libraries
Get Annexon Inc Fundamental Data
Annexon Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -216 468 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.3584
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Annexon Inc News
New
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamm...
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Annexon Biosciences BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies ai...
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More
Bet_Noire / iStock via Getty Images Quick Read Stocks continued higher on Monday as the “Santa Claus” rally appears to be here. Small-caps were the big winner Monday as the Russell 2000 pushed h...
Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development
Annexon Inc. (NASDAQ:ANNX) is one of the best multibagger penny stocks to buy right now. On December 1, Clear Street initiated coverage of Annexon Inc. (NASDAQ:ANNX) with a Buy rating and a $17 price ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.